Solve's questions to Moderna Inc (MRNA) leadership • Q1 2025
Question
Solve, on for Luca Issi, asked about recent political commentary on single-antigen vaccines and sought reassurance that Moderna's upcoming PDUFAs would be reviewed based on science rather than politics.
Answer
President Stephen Hoge affirmed the company's confidence in its robust clinical data and the scientific review process. He stated that interactions with the FDA have been "business as usual" and are based on large, randomized efficacy studies. He also noted that Moderna develops both single-antigen and multi-antigen products, believing in the value of both approaches.